TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06222021

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic analysis of polymorphism of membrane receptors involved in lactate transport
Description: The DNA extracted from the blood samples (through extractor MagCore) will then undergo gene sequencing by Sanger sequencing and/or Custom NGS (Next Generation Sequencing) panels and will be used to identify nucleotide variants within genes involved in lactate transport (MCT-1/4, GPR81).
Study: NCT05358327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study: NCT05026086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure biofeedback
Description: 10 patients will be treated with isometric exercises and pressure biofeedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isometric exercises
Description: 10 patients will be treated with isometric exercises
Study: NCT06301841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental
Description: At day 3, clinicians have to consider all the early microbiological results (including the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux) and procalcitonin, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation.~Discontinuation is encouraged in case of no bacteria documentation and a procalcitonin \< 1 ng/L; discontinuation is even encouraged if a viral documentation is concurrently obtained. In case of no bacteria documentation and a procalcitonin \> 1 nd/L, antibiotic continuation is encouraged for additional two days.~In case of bacteria documentation, antibiotic continuation is encouraged, but with narrowing the spectrum as much as possible. The duration of antibiotics is based on a procalcitonin algorithm: procalcitonin \< 0.1 nd/l: discontinuation; 0.1 ng/l \< procalcitonin \< 0.25 ng/l: additional 1 day; procalcitonin \> 0.25 ng/l: additional 2 days.
Study: NCT05672797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellth app
Description: The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellth app
Description: The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit training
Description: Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue).
Study: NCT05475821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-990
Description: Oral Tablet
Study: NCT06532435

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: DHA & ARA Candy
Description: Parpicipants need to eat 1-2 candy daily, for 4 consective weeks
Study: NCT05892133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Description: 3 sessions/ week. leg press at \~85% of one repetition maximum for 8 weeks
Study: NCT05923489

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Routine Angiography Follow-up
Description: Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine Clinical Follow-up
Description: Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
Study: NCT05866835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manufacture of custom-made IOP
Description: Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~* digital recording of the maxillary and mandibular dental arches~* mandibular wedging performed with an inter-arch piece~* digital recording of the inter-arch position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation tests
Description: Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~* At rest, standing still.~* During a 4 minute run on a treadmill at 50% of MAS.~* During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of comfort level:
Description: Collection from participants (self-questionnaire)
Study: NCT05126524

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: Observational study, no intervention performed
Study: NCT05115500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2
Description: RC48-ADC combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2
Study: NCT04950881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided vagus nerve block
Description: Before the operation starts, patients received the ultrasound guided vagus nerve block. A 50mm Braun nerve stimulation needle is guided by the ultrasonic beam to insert into the carotid sheath and 10ml of lidocaine or ropivacaine is injected.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bradycardia Treatment
Description: If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradycardia Treatment
Description: If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
Study: NCT05629533

Intervention type: DEVICE
Intervention: SimpleSense
Description: The study is observational only. No interventions will be triggered by the SimpleSense device

Intervention type: DEVICE
Intervention: SimpleSense
Description: The study is observational only. No interventions will be triggered by the SimpleSense device
Study: NCT04858659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK101-002 placebo
Description: 1 tablet at each time, 2 times a day
Study: NCT04486924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globe Mapping and Ablation System
Description: Prospective, non-randomized, open-label clinical study.
Study: NCT05252884

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: calcium correction according to PTH levels
Description: A PTH blood test will be performed 4 hours post-thyroidectomy. If the PTH result is \>15 pg/mL, the patient will be discharged without calcium intake; if PTH \< 15 pg/mL, start a dose of 1200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine postoperative calcium and calcitriol
Description: The patient will receive a dose of 1,200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days, starting on the same day as the intervention.
Study: NCT06414460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM3412
Description: ISM3412 will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM3412
Description: ISM3412 will be administered orally once daily.
Study: NCT05127499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercises
Description: progressive relaxation exercises will do
Study: NCT05899335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartCP (mobile phone app)
Description: As described
Study: NCT05016713

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine mouthwash is added to the oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.~If any participant shows any signs of CHX hypersensitivity, the intervention will be discontinued.
Study: NCT06515769

Intervention type: DIAGNOSTIC_TEST
Intervention: TERMOGRAPHY
Description: Obtaining an image of the foot using a thermographic camera

Intervention type: DIAGNOSTIC_TEST
Intervention: TERMOGRAPHY
Description: Obtaining an image of the foot using a thermographic camera
Study: NCT05610462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Exercise Training Program
Description: The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
Study: NCT04705727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Formoterol Drug Combination
Description: This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulisation of terbutaline
Description: Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
Study: NCT05016713

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interdental brush
Description: Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interdental brush
Description: Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride-based toothpaste
Description: Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
Study: NCT04829383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1,200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg
Study: NCT05602259

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: induced sputum
Description: After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (\> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung biopsy
Description: As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchoalveolar lavage
Description: When available, the remaining material from a patient's bronchoalveolar lavage will be collected.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood draw
Description: As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected.
Study: NCT06188052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
Study: NCT05016713

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride-based toothpaste
Description: Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
Study: NCT05852015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment-as-Usual (TAU)
Description: TAU consists of weekly outpatient-based group therapy for substance use disorder

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Description: TAU consists of weekly outpatient-based group therapy for substance use disorder
Study: NCT05726292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is being used in this study as an experimental drug combined with other treatments for prostate cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.
Study: NCT04632095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve replacement due to sternotomy
Description: conventional surgery of aortic stenosis
Study: NCT05726292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Sugar Pill)
Description: This would be a sugar pill consisting of 2 softgels. This is not an experimental drug or treatment.
Study: NCT04632095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve replacement due to parasternal right anterior mini-thoracotomy
Description: surgery of aortic stenosis in minimally invasive technique
Study: NCT05726292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: All participants in this study, who meet the requirements to participate, will get Androgen Deprivation Therapy (ADT; a form of hormone therapy) continuously before their radical prostatectomy surgery. As part of this study, ADT consists of one injection every 1-3 months. In this study, ADT is a gonadotropin releasing hormone (GnRH) agonists or antagonist; the choice of which brand of ADT to use is up to your treating physician. GnRH agonists and antagonists are drugs that lower the production of androgens (male hormones) in your body. Prostate cancer cells usually require androgens, such as testosterone, to grow.~Androgen Deprivation Therapy (ADT) has been approved by United Stated Food and Drug Administration (US FDA) to treat patients with prostate cancer but is not approved to treat patients prior to prostatectomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: All participants in this study, who meet the requirements to participate, will get Androgen Deprivation Therapy (ADT; a form of hormone therapy) continuously before their radical prostatectomy surgery. As part of this study, ADT consists of one injection every 1-3 months. In this study, ADT is a gonadotropin releasing hormone (GnRH) agonists or antagonist; the choice of which brand of ADT to use is up to your treating physician. GnRH agonists and antagonists are drugs that lower the production of androgens (male hormones) in your body. Prostate cancer cells usually require androgens, such as testosterone, to grow.~Androgen Deprivation Therapy (ADT) has been approved by United Stated Food and Drug Administration (US FDA) to treat patients with prostate cancer but is not approved to treat patients prior to prostatectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy is surgery to remove the entire prostate gland and surrounding lymph nodes to treat men with localized prostate cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy is surgery to remove the entire prostate gland and surrounding lymph nodes to treat men with localized prostate cancer.
Study: NCT04935489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form
Description: The intervention is used regularly for patients with treatment resistant depression, however, in this trial it will be given multiple times per day and over less days than the usual protocol
Study: NCT05100199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA X
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA X
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA X
Description: Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection
Study: NCT05852015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Mindfulness Treatment
Description: The digital mindfulness-based treatment is a multimedia app-based program teaching mindfulness skills to facilitate recovery from substance use disorder
Study: NCT06188052

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
Study: NCT06417164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Movement Training Group
Description: The program control group will use traditional physical training methods, while the experimental group will use a training program based on FMS functional movement design. The experimental group will receive a 12-week FMS functional movement training intervention, with each session lasting 40 minutes. The experimental group will be divided into two phases, a corrective intervention phase and a capacity enhancement phase, and the main assessment criteria will include the seven movements of the FMS Functional Movement Test (squat, hurdle step, deep squat, shoulder mobility, active straight leg raise, trunk stabilizing push-ups, and trunk rotational stabilization), as well as the ability to control the body's dynamic and static postures during aerobic exercise.
Study: NCT04762017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCS-05 +SoC (corticosteroid) IV administration
Description: OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SoC (corticosteroid) IV administration
Description: Placebo + SoC (corticosteroid) IV administration for 5 consecutive days
Study: NCT06749210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tango
Description: The intervention being studied is a 16 session intervention (2x4-week modules), delivered over an 8-week period by community-based individuals with expertise in dance and patient care and certified in Adapted Tango or AdapTango dance instruction. Steps available to teach, including order and cues to teach them, are detailed in Hackney's AdapTango manual. All steps are based on the Argentine Tango steps that emerged within working class community centers in Buenos Aires, Argentina (milongas) in the late 1800s and have been adapted by the investigators for use as medical exercise among people with mobility deficits. Of note, Argentine Tango is distinct from, and the precursor for, the American Tango style of competitive ballroom dance: where American Tango highlights showmanship and complicated footwork, Argentine Tango prioritizes connection between partners and musicality within a basic walk motion.
Study: NCT06749418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.